Impact Analytics

ReimbursementIQ is offering two-hour executive briefings on “Impact Analytics” to chief officers, senior executives, and strategic work teams within Life Science companies.

The in-person briefings are expected to transform Medical Affairs, HEOR/Value, Market Access, and Commercialization (Marketing and Sales) functions by revealing the extreme visibility that data science is bringing to the U.S. healthcare market—especially to individuals, employers, and other healthcare purchasers.

Health plan buyers  want more value for their money, and Life Science leaders need to understand the level of transparency that data science gives those bearing the burden of healthcare cost escalation.

In an April 5, 2018 report, the Pharmaceutical Research and Manufacturers Association (PhRMA) highlighted 39 value-based contracts between pharmaceutical companies and savings-minded healthcare stakeholders. The bulk of these purchasing arrangements centered on discounted, bundled, capitated, pay-for-performance, and outcomes-driven pricing for payers.

Next-generation contracts will move toward 360-degree impact accountability across stakeholders. Data science vendors offering healthcare purchasers greater visibility into the human, business, and social results of clinical interventions. The Life Science sector can no longer expect business as usual.

ReimbursementIQ’s two-hour briefings describe the competencies that mission-driven Life Science companies need to win next-generation value-based contracts; to meet new performance, outcomes, and impact accountabilities; and to deliver real, lasting results.

The briefings feature three health industry pioneers and how each has improved performance, outcomes, and impacts at the level of community care, healthcare, and self-care. Life Science leaders get first-hand exposure to state-of-the-art data visualizations, dashboards, and scorecards that provide real-time reporting on the wellbeing, productive capacity, and socioeconomic status of individuals, organizations, and communities.

With 360-degree accountability on the horizon, Life Science executives learn how their Medical Affairs, Market Access, and Marketing teams should use impact analytics to

  1.  improve economic, clinical, and humanistic outcomes (ECHOs);
  2.  achieve the Triple/Quadruple Aim of reduced per capita costs, improved population health, and enhanced patients and provider experiences;
  3.  reduce the incidence, prevalence, and cost of diseases and other adverse conditions;
  4.  increase the wellbeing, productive capacity, and socioeconomic status of individuals, organizations, and communities; and
  5.  contribute to a better functioning society.

Briefed on U.S. healthcare’s digital transformation and growing transparencies, Life Science leaders attending “Impact Analytics” gain strategic advantages in value-based, impact-accountable contracting.

To learn more about Impact Analytics and impact-accountable market, corporate, and product development, please visit reimbursementiq.com or write smolina@reimbursementiq.com.

Similar Posts